Elan Corporation, plc Message Board

Thanks for the reply one-up. If a woman asks a doctor to get tested for breast cancer susceptibility, is the standard practice to advise the Myriad test first, or Brevagen? It seems that the Brevagen test would be the more likely test due to the 75% probability? Both tests seem to be complementary to each other...

Sentiment: Buy

It's been awhile since I've kept up with this company. Can you provide an explanation how Brevagen is different from the BRCA test used (assume by Myriad?) Is there a relationship b/w the two companies? TIA

Sentiment: Buy

Just found out that my broker Fidelity has stopped reinvesting dividends from French companies. It's all going to my cash account. I'm told they made this change in January and it was not communicated to their customers. The reason for this action is apparently a new French reinvestment fee that Fidelity did not want to deal with. So for those of you in the reinvestment phase and using Fidelity, you might want to verify this.

Just found out that my broker Fidelity has stopped reinvesting dividends from French companies. It's all going to my cash account. I'm told they made this change in January and it was not communicated to their customers. The reason for this action is apparently a new French reinvestment fee that Fidelity did not want to deal with. So for those of you in the reinvestment phase and using Fidelity, watch out!

Quick back of envelope calc:
Given the assumptions of just under $2B in sales in year 2 with 18% royalty, that comes out ~ $0.15/share. Not alot (just over 1%), but better than the current zero. And it scales up with higher sales (and higher royalty).